Chronic granulomatous disease
Chronic granulomatous disease is an inherited disorder of the NADPH oxidase complex in which phagocytes are defective in generating the microbicidal reactive oxidant superoxide anion and its metabolites, hydrogen peroxide, hydroxyl anion, and hypohalous acid. As a result of the defect in this key host defense pathway, CGD patients suffer from recurrent life-threatening bacterial and fungal infections. CGD is also characterized by abnormally exuberant inflammatory responses leading to granuloma formation, such as granulomatous enteritis, genitourinary obstruction, poor wound healing, and dehiscence. CGD affects approximately 1 in 200,000 persons.
The phagocyte NADPH oxidase functions to rapidly generate superoxide anion by transferring electrons from NADPH to molecular O 2 in response to physiologic stimuli such as phagocytosis. The cytochrome, composed of gp91 phox (phox, phagocyte oxidase) and p22 phox , is embedded in membranes. In neutrophils, approximately 85% of the cytochrome is in the membranes of specific granules or gelatinase-containing granules, and the remainder is present in the plasma membrane and in secretory granules [1, 2] . The NADPH binding site is located on the cytoplasmic side of membranes. Upon activation of the oxidase, the cytoplasmic subunits p47 phox , p67 phox , and p40 phox appear to translocate en-bloc to the membrane-bound cytochrome. Activation of rac, a member of the low molecular weight GTP-binding proteins, and translocation of rac to the membrane-bound cytochrome are also critical for NADPH oxidase activation [3, 4] .
NADPH is oxidized to NADP + , and electrons are transported down a reducing potential gradient to FAD and then possibly to 2 non-identical heme groups. On the vacuolar or extracellular side of the membrane, the final step in the electron transport chain occurs when oxygen accepts an electron and is converted to superoxide anion. The net equation Recently, Reeves et al. [5] shed new light on the mechanism by which NADPH CGD patients have recurrent infections with a subset of catalase producing pathogens [12] [13] [14] . A national database describing the spectrum of infections in 368 patients with CGD has been created [15] . The most common pathogens include:
Aspergillus species (pneumonia, osteomyelitis), Staphylococcus aureus (suppurative adenitis, subcutaneous infections, liver abscess), Serratia species (osteomyelitis, pneumonia), Nocardia species, and Burkholderia cepacia (pneumonia and sepsis).
Invasive aspergillosis in CGD
Invasive aspergillosis is the most important cause of mortality in CGD [16, 17] .
CGD patients are susceptible to a broad spectrum of opportunistic filamentous fungi, but
Aspergillus infection is by far the most common. Despite the routine use of interferongamma prophylaxis (see below), fungal infections have remained a persistent problem with an incidence of 0.1 fungal infections per patient year [15] . Patients with X-linked CGD appear to be at increased risk for invasive aspergillosis compared with the autosomal recessive forms [18, 19] . Invasive aspergillosis may be the first manifestation of CGD. Infection usually manifests within the first 2 decades of life [18] . Invasive aspergillosis in CGD patients during the neonatal period is occasionally observed [20, 21] . Very rarely, invasive aspergillosis may occur in a female carrier of X-linked CGD in whom the random process of lyonization (X-chromosome inactivation) has led to a skewing of the circulating normal neutrophil population to less than 10% oxidant competent [7] . CGD patients often do not have typical symptoms and signs of infection [12] .
Aspergillus fumigatus and
Even in the setting of life threatening infections, CGD patients may be asymptomatic or have mild non-specific symptoms. Fever and leukocytosis may be absent, and an elevated sedimentation rate may be the only abnormal laboratory test [12] . In a review of aspergillosis in CGD patients at the NIH, one third of patients were asymptomatic at diagnosis and only ~20% were febrile [18] . In many of these patients, a pulmonary infiltrate on routine screening chest x-ray or CT scan was the first indication of an infection. The white blood cell count was ≤10,000/µl in 13/23 cases and the sedimentation rate was ≤40 mm/hr in 9/20 cases.
Patients with CGD may have concurrent bacterial and fungal infections [22] . It is therefore essential to establish a culture diagnosis when feasible prior to initiating antimicrobial therapy. Biopsy material should be submitted for pathology as well as bacterial and fungal culture, including Nocardia. In addition, recrudescent fungal infection can occur after initial control of infection had been achieved --a feature that is common with A. nidulans [18] . Thus, a high level of vigilance in searching for infection is necessary in caring for CGD patients. Frequent radiographic evaluation (e.g., chest radiographs during routine clinic visits and CT scans in patients with fever or focal signs)
is critical to making early diagnoses.
Pulmonary infection is the most common site of invasive aspergillosis in CGD.
The clinical presentation is variable, but well-defined syndromes exist. The radiographic appearance is usually an infiltrate, mass, or nodule, and multiple lesions may be present.
In contrast to patients with chemotherapy-induced neutropenia, hyphal angioinvasion usually does not occur in CGD. Thus, a halo sign (reflecting angioinvasion with surrounding tissue ischemia), cavitated lesions, and pulmonary infarction are not typical features of CGD. In early disease, an acute neutrophilic response is observed. As shown in a lung biopsy of fungal pneumonia (Figure 2 ), neutrophils surround and adhere to the hyphal element, but the hypal element remains intact, reflecting the impaired microbicidal killing. Rarely, pulmonary Aspergillus infection presents as an acute and sometimes lifethreatening miliary pneumonitis due to acute massive inhalation (e.g., during mulching) that requires combination therapy with an antifungal agent and corticosteroids ( Figure 3) . (Bottom) Chest CT of a patient with massive inhalation of fungal spores leading to acute hypoxia, fever and requiring intubation and mechanical ventilation (Pending).
Invasive pulmonary aspergillosis typically causes a chronic indolent infection in CGD. The terms, "chronic septic granulomatosis" and "microgranulomatous aspergillosis" have been used to describe these lesions [23] . A chronic diffuse nodular pneumonia may also occur [24] . Lesions typically contain a mixed inflammatory cell response consisting of neutrophils, histiocytes, and lymphocytes ( Figure 4 ). fumigatus hyphae led to an exuberant inflammatory response in X-linked CGD mice, but only a modest self-limited inflammatory response in wildtype controls [26] . Within 24h of challenge, an acute alveolar neutrophilic response occurred in CGD mice, accompanied by an increase in proinflammatory cytokines. Within 1 week, pyogranulomatous lesions developed which persisted for at least 6 weeks. These observations indicate that there is an intrinsic defect in regulation of inflammatory responses in CGD independent of the defect in microbicidal killing.
Pulmonary invasive aspergillosis may spread locally to involve the vertebrae and chest wall structures. This is particularly common with A. nidulans infection [18] .
Fungal infection may be limited to the bone or soft tissue, and such infections typically respond to surgical debridement and antifungal therapy [16] . Disseminated infection can involve several sites, including the central nervous system, internal organs, and the skin.
Cutaneous infection may represent primary localized infection or disseminated disease [27] .
Therapy of invasive aspergillosis
Standard therapy for invasive aspergillosis has been high dose conventional amphotericin B (1-1.5 mg/kg daily). In patients with CGD, a prolonged duration of antifungal therapy was typically required to control filamentous fungal infection, which often entails significant nephrotoxicity. Lipid formulations of amphotericin B appear to be more effective with less nephrotoxicity and infusion-related toxicity than conventional amphotericin B, based on non-comparative and compassionate use studies. Voriconazole has been the most extensively studied of this group of azoles. In a non-comparative study of 116 patients with invasive aspergillosis for whom voriconazole was given either as initial (52%) or salvage (48%) therapy, a complete or partial response occurred in 48%, with a more favorable prognosis in the initial therapy group [28] .
Voriconazole was also compared with conventional amphotericin B (1.0 to 1.5 mg/kg daily) as initial therapy in an open, randomized study of patients with invasive aspergillosis [29] . A total of 144 patients in the voriconazole arms and 133 patients in the amphotericin B arm with definite or probable aspergillosis received at least 1 dose of therapy. Voriconazole was more effective than amphotericin B (53% with complete or partial response vs. 32%, respectively) and had improved survival at 12 weeks (71% vs.
58%, respectively). Voriconazole had a superior response rate in both neutropenic and non-neutropenic patients [29] . Most of the patients in this study had a hematologic malignancy or were hematopoietic transplant recipients. In addition to systemic antifungal therapy, debridement or excision of localized fungal infection is advised when such sites are surgically accessible. In particular with A.
nidulans, multiple debridements may be required when chest wall structures and vertebrae are involved [18] . Adjunctive therapy with granulocyte transfusions is discussed below.
Prophylaxis against fungal infections
The routine use of antibacterial prophylaxis, usually with trimethoprimsulfamethoxazole, has significantly reduced the frequency of severe bacterial infections in CGD. However, fungal infections have remained a persistent problem with an incidence of 0.1 fungal infections per patient year [15] . In a long-term follow-up of 39 patients with CGD, Liese et al. [19] reported an increase in the frequency of fungal infections under antibiotic prophylaxis from a mean incidence of 0.2 to 1.9 serious infections per 100 patient months. However, Margolis et al. [32] found no change in the rate of fungal infections with antibacterial prophylaxis. These data underscore the need for effective antifungal prophylaxis.
In a European prospective open label study of itraconazole prophylaxis, the rate of Aspergillus infections was reduced compared with historical controls, and the drug was well tolerated [17] . A randomized, double-blind, placebo-controlled cross over study of itraconazole prophylaxis has recently been completed at the NIH [33] . Thirtynine patients over 5 years of age were enrolled. One serious fungal infection occurred in itraconazole recipients versus 7 cases in the placebo group. No significant toxicity was observed. This study supports the routine use of itraconazole prophylaxis in CGD.
This study employed itraconazole capsules, which have erratic bioavailability. In approximately half of the plasma samples drawn during itraconazole therapy, the level was in the range (< 0.3 ug/ml) that is considered sub-therapeutic. The cyclodextrin (oral suspension) formulation of itraconazole has enhanced and more reliable bioavailability.
Regardless of which oral formulation is used, monitoring of plasma levels is advised based on the experience using itraconzaole prophylaxis in patients with hematologic malignancies and hematopoietic transplantation in which therapeutic levels of itraconazole were protective [34, 35] .
Interferon-gamma
Interferon-gamma (IFN-g) is a macrophage activating factor critical in host defense against intracellular infections such as Leishmania and Mycobacteria species in humans and mice [36] . In clinical trials in patients with cancer [37] and with lepromatous leprosy [38] , IFN-g increased H 2 0 2 generation in circulating monocytes, providing a rationale for evaluating IFN-g in CGD. In preliminary studies, addition of recombinant IFN-g in vitro to phagocytes from some, but not all, CGD patients augmented superoxide production [39, 40] . Augmentation of superoxide production was observed in phagocytes from cytochrome positive X-linked and the majority of autosomal recessive CGD patients, as well as in ~30% of X-linked cytochrome negative patients. In a study of patients with cytochrome positive X-linked CGD, two consecutive subcutaneous injections of IFN-g resulted in a 5-to 10-fold increase in superoxide production from granulocytes and monocytes [41] . The effect lasted for more than two weeks and was associated with an increase in bactericidal activity. Rex et al. [42] showed that administration of IFN-g to CGD patients augmented the in vitro ability of CGD neutrophils to damage Aspergillus hyphae.
Given these promising results, a multicenter, randomized, double blinded, placebo-controlled study of prophylactic IFN-g (50 ug/m 2 subcutaneously thrice weekly) was conducted [43] . One hundred and twenty eight CGD patients (67% Xlinked and 33% autosomal recessive) were enrolled. Prophylactic IFN-g reduced the number of serious infections by over 70%, and was beneficial in both the X-linked and autosomal recessive forms of CGD. In contrast to earlier studies, no significant differences occurred between the IFN-g and placebo groups with regard to reactive oxidant generation, cytochrome b expression, or in vitro bacterial killing. Subsequent studies in CGD patients [44, 45] and CGD mice [46] confirmed that IFN-g did not improve NADPH oxidase function or increase levels of its constituent proteins.
The benefit of IFN-g prophylaxis in CGD likely occurs through augmentation of oxidant-independent antimicrobial pathways. IFN-g increases TNF-alpha production, tryptophan metabolism, expression of Fc-gammaR1 receptors on phagocytes, B 2 -integrin expression on monocytes, granule protein synthesis, and MHC-expression [36, 47] .
A 10-year follow-up phase IV study of CGD patients receiving IFN-g (50 ug/m 2 )
at NIH suggests that the drug is, in general, well-tolerated and the benefits appear sustained over and above that achieved with antibacterial prophylaxis alone.
The optimal dose and frequency of IFN-g remain to be determined. Ahlin et al.
[48] studied a small group of patients with either X-linked or autosomal CGD, receiving IFN-g 100 ug/m 2 . They found enhancement of ex vivo neutrophil functions and killing of A. fumigatus hyphae compared to CGD patients receiving the standard 50 ug/m 2 dose.
We do not know whether the therapeutic use of IFN-g after the onset of fungal infection is beneficial. Use of IFN-g as adjunctive therapy for invasive aspergillosis in CGD is limited to case reports [49] . A randomized, placebo controlled study of IFNgamma as adjunctive therapy in patients with invasive aspergillosis (not restricted to CGD) has been initiated.
Granulocyte transfusions
Granulocyte transfusion in CGD is supported by the principle that a small number of normal phagocytes may be able to complement the oxidative defect in a large number of CGD phagocytes. In vitro, a small proportion of normal neutrophils mixed with CGD neutrophils kill A. fumigatus hyphae as well as a population consisting entirely of normal neutrophils [50] . The likely explanation is that H 2 0 2 generated by the minority of normal neutrophils can diffuse into CGD neutrophils and provide the necessary reagent to generate hypohalous acid and hydroxyl anion [50, 51] . Transfused granulocytes retain respiratory burst activity and appear to traffic normally based on their recovery from sites of infection (e.g. wound drainage sites from liver abscesses), from mouth rinse preparations, from bronchoalveolar lavage, and from neutrophil exudate in experimental skin windows [52] [53] [54] .
Over the past 20 years, we have used granulocyte transfusions in CGD in life threatening infections and in infections refractory to antimicrobial and surgical treatment.
Granulocyte transfusions are generally well tolerated, but adverse effects include fevers, development of leukoagglutinins leading to rapid loss of transfused granulocytes, and rarely, pulmonary leukostasis. The likelihood of pulmonary leukostasis may be increased if amphotericin B and granulocytes are administered concomitantly [55] ; therefore granulocyte transfusions and amphotericin B should be administered several hours apart.
One concern regarding granulocyte transfusions is alloimmunization, which is of theoretical concern for patients under consideration for bone marrow transplantation.
Bone marrow transplantation
Because CGD results from a defect in hematopoietic stem cells, bone marrow transplantation (BMT) is a rational option to establish a stable population of normal myeloid progenitors. Myeloablative BMT has been reported in at least 10 CGD patients and was curative in all 6 reported cases since 1984 [56] [57] [58] [59] [60] . Most cured patients had 100% circulating donor myeloid cells. In one patient, a stable chimeric population of circulating granulocytes consisting of 10-15% normal cells conferred protection against infections, similar to X-CGD carriers [58] [59] [60] .
The morbidity and mortality associated with BMT have militated against its routine use in CGD. Horwitz et al. [61] The goal of gene therapy in CGD is to achieve a stable population of gene corrected myeloid precursors, which give rise to a biologically significant number of peripheral phagocytes. In a pilot study, gene therapy in patients with p47 phox-/-CGD led to detectable, albeit miniscule, circulating oxidant producing neutrophils for as long as 6 months [79] . In the short term, it is conceivable that infusions of gene corrected progenitors that persist for a few months may be beneficial as adjunctive therapy for serious infections [79] . Successful gene therapy in CGD and in other hematopoietic disorders is limited by the transduction efficiency of myeloid precursors ex vivo and by the ability of corrected cells to replace uncorrected cells in vivo.
In X-linked CGD mice, correction of the host defect either by bone marrow transplantation or retroviral-mediated gene transfer led to protection against challenge by
Aspergillus and bacterial pathogens [77, 80] . Host defense was improved even with a limited proportion of gene-corrected neutrophils. Therefore, maintenance of a chimeric state in which there is a small population of circulating gene-corrected neutrophils may be of benefit in invasive aspergillosis in CGD patients.
Summary
Invasive aspergillosis is the most important cause of mortality in CGD CGD patients are susceptible to a broad spectrum of opportunistic filamentous fungi, but Aspergillus infection is by far the most common. Current approaches should include prophylaxis with IFN-g and itraconazole. Vigilance should be maintained in terms of radiographic screening even in the absence of symptoms and agressively pursuing microbiologic diagnosis of suspicious lesions. Voriconazole is our initial drug of choice for invasive aspergillosis. For such infections, granulocyte transfusions may be helpful. Bone marrow transplantation and gene therapy are promising methods for immune augmentation.
